Steven Simoens, Arnold G. Vulto, & Pieter Dylst. (2021). Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study. MDPI AG.
Chicago Style (17th ed.) CitationSteven Simoens, Arnold G. Vulto, and Pieter Dylst. Simulating Costs of Intravenous Biosimilar Trastuzumab Vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study. MDPI AG, 2021.
MLA (9th ed.) CitationSteven Simoens, et al. Simulating Costs of Intravenous Biosimilar Trastuzumab Vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study. MDPI AG, 2021.
Warning: These citations may not always be 100% accurate.